Axim contracts Israel-based CRO for cannabidiol chewing gum clinical trials

By Melissa Fassbender

- Last updated on GMT

Axim Biotechnologies develops cannabis-based pharmaceutical, nutraceutical, and cosmetic products.(Image: iStock/Johny87)
Axim Biotechnologies develops cannabis-based pharmaceutical, nutraceutical, and cosmetic products.(Image: iStock/Johny87)

Related tags Clinical trial

An Israel-based contract research organization (CRO) is conducting a Ph II clinical trial for Axim’s cannabidiol (CBD) and Gabapentin chewing gum product.

Under the services agreement, the unnamed CRO will conduct the double blind, randomized, single-center Phase II trial for AXIM Biotechnologies, Inc.

The goal is to demonstrate the efficacy of Axim’s Gabapentin/CBD chewing gum product in approximately 30 study participants to treat restless leg syndrome (RLS).

We are working now on the protocol of the preclinical trial and AXIM is working in parallel to finalize the formulation​,” Axim CEO George Anastassov, MD, DDS, MBA, told Outsourcing-Pharma.com.

In March​, Axim announced it had contracted the global CRO Ora, Inc. to help advance its cannabinoid-based therapeutics. 

The company's flagship products include CanChew, a CBD-based controlled release chewing gum, CanChew+, which is undergoing clinical trials​ in patients with IBS, and MedChew Rx, a combination CBD/THC gum also in clinical trials.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Webinars

Headlines